You are viewing the site in preview mode

Skip to main content

Table 1 The comparison of baseline characteristics of the participants

From: Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial

Variable Mean ± SD
Placebo (n = 21) 		Mean ± SD
Ellagic acid (n = 21) 		P1
Age (years) 44.04 ± 6.88 47 ± 5.06 0.701
Height(cm) 163.71 ± 9.12 162.43 ± 10.59 0.814
Weight (kg)
 Before 68.95 ± 9.02 67.23 ± 10.24 0.621
 After 68.49 ± 9.21 66.98 ± 10.31 0.59
 P2 0.78 0.619  
Body mass index (K g/m2)
 Before 25.61 ± 0.86 25.32 ± 1.07 0.562
 After 25.43 ± 0.9 25.22 ± 1.09 0.604
 P2 0.719 0.807  
Physical activity
 Before 37.27 ± 2.78 36.15 ± 2.99 0.132
 After 37.5 ± 3.31 36.43 ± 2.89 0.108
 P2 0.429 0.49  
Metformin dose 1643.17 ± 377.88 1610.4 ± 362.07 0.88
  1. Data are expressed as means ± SD
  2. P1: Comparison of the mean of baseline characteristics between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of baseline characteristics in each group at baseline and end of study (Paired samples t-test)
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us

\